Three-Drug Polypill Improves BP and Outcomes After Intracerebral Hemorrhage: Study
Australia: Researchers have found in the placebo-controlled TRIDENT trial that among patients with intracerebral hemorrhage, adjunctive treatment with a three-drug polypill demonstrated significant clinical benefits.
The investigational GMRx2 polypill, which combines telmisartan, amlodipine, and indapamide, resulted in improved blood pressure control, fewer recurrent strokes, and a reduced incidence of major cardiovascular events when added to standard therapy. However, the benefits may be limited to patients who can tolerate the regimen, as a notable proportion discontinued treatment early due to increases in serum creatinine.
A large international team led by Craig S. Anderson conducted the TRIDENT trial to evaluate whether a fixed-dose combination of three antihypertensive agents could offer superior protection against recurrent stroke in patients recovering from intracerebral hemorrhage. Although blood pressure reduction remains the cornerstone of secondary stroke prevention, uncertainty has persisted regarding the added value of combination therapy delivered in a single pill alongside usual care.
The double-blind, randomized, placebo-controlled trial, published in the New England Journal of Medicine, enrolled 1,670 clinically stable patients with a history of intracerebral hemorrhage and a baseline systolic blood pressure ranging from 130 to 160 mmHg. All participants initially underwent a two-week active run-in phase during which they received a once-daily low-dose triple combination of telmisartan (20 mg), amlodipine (2.5 mg), and indapamide (1.25 mg). Following this phase, patients were randomly assigned to either continue the triple-pill regimen or switch to a matching placebo, while continuing standard antihypertensive therapy.
The key findings of the study were as follows:
- Over a median follow-up of 2.5 years, the triple-pill group showed a notable reduction in recurrent stroke compared to placebo.
- Recurrent stroke occurred in 4.6% of patients receiving the triple pill versus 7.4% in the placebo group, reflecting a 39% relative risk reduction.
- Blood pressure control was significantly better with the triple-pill regimen, with a mean systolic blood pressure of 127 mm Hg compared to 138 mm Hg in the placebo group.
- The triple combination therapy was associated with a lower incidence of major cardiovascular events (6.6% vs. 9.8% with placebo).
- These results indicate added cardiovascular protection with more intensive and sustained blood pressure reduction in high-risk patients.
- Serious adverse events were broadly similar between groups, occurring in 23.2% of the triple-pill group and 26.0% of the placebo group.
- Discontinuation due to adverse events was higher in the triple-pill group (13.6%) compared to placebo (6.0%).
- The most common reason for discontinuation was a significant increase in serum creatinine, highlighting the importance of monitoring renal function.
Overall, the findings suggest that a low-dose, fixed-combination antihypertensive polypill could represent an effective strategy for secondary prevention after intracerebral hemorrhage. While the approach offers meaningful reductions in recurrent stroke and cardiovascular events, its clinical utility may depend on patient tolerance and vigilant safety monitoring.
Reference:
DOI: 10.1056/NEJMoa2515043
Next Story